148 related articles for article (PubMed ID: 36531872)
1. Circulating Anti-Rituximab Antibodies Do Not Affect Response to Rituximab in Steroid-Dependent Nephrotic Syndrome.
Angeletti A; Bruschi M; Colucci M; Kajana X; La Porta E; Caridi G; Lugani F; Ravani P; Vivarelli M; Cravedi P; Ghiggeri GM
Kidney Int Rep; 2022 Nov; 7(11):2509-2512. PubMed ID: 36531872
[No Abstract] [Full Text] [Related]
2. Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.
Ravani P; Bonanni A; Rossi R; Caridi G; Ghiggeri GM
Clin J Am Soc Nephrol; 2016 Apr; 11(4):710-20. PubMed ID: 26585985
[TBL] [Abstract][Full Text] [Related]
3. New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?
Basu B; Angeletti A; Islam B; Ghiggeri GM
Front Immunol; 2022; 13():805697. PubMed ID: 35222385
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis.
Kronbichler A; Bruchfeld A
Nephron Clin Pract; 2014; 128(3-4):277-82. PubMed ID: 25401966
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.
Sinha A; Bhatia D; Gulati A; Rawat M; Dinda AK; Hari P; Bagga A
Nephrol Dial Transplant; 2015 Jan; 30(1):96-106. PubMed ID: 25121488
[TBL] [Abstract][Full Text] [Related]
6. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.
Benz K; Dötsch J; Rascher W; Stachel D
Pediatr Nephrol; 2004 Jul; 19(7):794-7. PubMed ID: 15071769
[TBL] [Abstract][Full Text] [Related]
7. Successful Pregnancies in a Patient with Childhood-onset Steroid-dependent Nephrotic Syndrome during Rituximab Maintenance Therapy.
Nara M; Kaga H; Saito M; Abe F; Saito A; Imaizumi C; Komatsuda A; Wakui H; Takahashi N
Intern Med; 2021 Sep; 60(18):2985-2989. PubMed ID: 33776000
[TBL] [Abstract][Full Text] [Related]
8. Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children.
Kamei K; Ishikura K; Sako M; Ito S; Nozu K; Iijima K
Pediatr Nephrol; 2020 Jan; 35(1):17-24. PubMed ID: 30564879
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for refractory focal segmental glomerulosclerosis.
Nakayama M; Kamei K; Nozu K; Matsuoka K; Nakagawa A; Sako M; Iijima K
Pediatr Nephrol; 2008 Mar; 23(3):481-5. PubMed ID: 17973121
[TBL] [Abstract][Full Text] [Related]
10. Anti-Neu5Gc Antibodies do not Affect Response to Human or Chimeric Monoclonal Anti-CD20 Antibodies in Children with Nephrotic Syndrome.
Angeletti A; Bruschi M; Kajana X; Lugani F; Candiano G; Ghiggeri GM
J Am Soc Nephrol; 2022 Nov; 33(11):1985-1987. PubMed ID: 35999046
[No Abstract] [Full Text] [Related]
11. Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible?
Dötsch J; Müller-Wiefel DE; Kemper MJ
Pediatr Nephrol; 2008 Jan; 23(1):3-7. PubMed ID: 17899207
[TBL] [Abstract][Full Text] [Related]
12. Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab.
Suri M; Tran K; Sharma AP; Filler G; Grimmer J
Int Urol Nephrol; 2008; 40(3):807-10. PubMed ID: 18491215
[TBL] [Abstract][Full Text] [Related]
13. Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome.
Bertrand Q; Mignot S; Kwon T; Couderc A; Maisin A; Cambier A; Baudouin V; Peyneau M; Deschênes G; Hogan J; Dossier C
Pediatr Nephrol; 2022 Feb; 37(2):357-365. PubMed ID: 34132894
[TBL] [Abstract][Full Text] [Related]
14. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
Ravani P; Bonanni A; Ghiggeri GM
BMJ Open; 2017 Mar; 7(3):e013319. PubMed ID: 28314744
[TBL] [Abstract][Full Text] [Related]
15. Rituximab treatment for adult patients with focal segmental glomerulosclerosis.
Ochi A; Takei T; Nakayama K; Iwasaki C; Kamei D; Tsuruta Y; Shimizu A; Shiohira S; Moriyama T; Itabashi M; Mochizuki T; Uchida K; Tsuchiya K; Hattori M; Nitta K
Intern Med; 2012; 51(7):759-62. PubMed ID: 22466834
[TBL] [Abstract][Full Text] [Related]
16. Rituximab therapy in nephrotic syndrome: implications for patients' management.
Sinha A; Bagga A
Nat Rev Nephrol; 2013 Mar; 9(3):154-69. PubMed ID: 23338210
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.
Kronbichler A; König P; Busch M; Wolf G; Mayer G; Rudnicki M
Wien Klin Wochenschr; 2013 Jun; 125(11-12):328-33. PubMed ID: 23624956
[TBL] [Abstract][Full Text] [Related]
18. Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximab.
Marasà M; Cravedi P; Ruggiero B; Ruggenenti P
BMJ Case Rep; 2014 Aug; 2014():. PubMed ID: 25155494
[TBL] [Abstract][Full Text] [Related]
19. Is rituximab effective in childhood nephrotic syndrome? Yes and no.
Kemper MJ; Lehnhardt A; Zawischa A; Oh J
Pediatr Nephrol; 2014 Aug; 29(8):1305-11. PubMed ID: 23820888
[TBL] [Abstract][Full Text] [Related]
20. Rituximab in The Management of Pediatric Steroid-Resistant Nephrotic Syndrome: A Systematic Review.
Jellouli M; Charfi R; Maalej B; Mahfoud A; Trabelsi S; Gargah T
J Pediatr; 2018 Jun; 197():191-197.e1. PubMed ID: 29680473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
